10-Q: International Isotopes Reports Q3 Loss Amid Supply Issues

International Isotopes Inc. reported an increased net loss for Q3 2025, driven by supply chain disruptions and an FDA Official Action Indicated, despite strategic growth initiatives.

Summary

• International Isotopes Inc. reported a net loss of $203,601 for the three months ended September 30, 2025, compared to net income of $150,251 for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss increased to $477,080 from $237,245 in the prior year period.
• Total product sales for the nine months ended September 30, 2025, increased by 2% to $10,172,036, up from $9,998,135 in 2024.
• Gross profit for the nine months decreased by 3% to $6,113,615 from $6,333,050 in 2024.
• Net cash provided by operating activities significantly decreased to $210,043 for the nine months ended September 30, 2025, from $568,215 in 2024.
• The company is in the process of divesting its Fluorine Products segment and Planned Uranium De-Conversion Facility for $12.5 million, with an expected net cash inflow of $10.2 million after debt repayment.
• An FDA inspection in April 2025 resulted in an Official Action Indicated (OAI) at the Idaho Falls facility, with corrective actions underway.
• Sales in the Theranostics Products segment decreased by 17% for the nine months due to temporary supplier outages and partial loss of a national account.
• Calibration & Reference Products segment sales increased by 57% for the nine months, recovering from a Cobalt-57 shortage in 2024, but faced a new global shortage of Gadolinium-153.
• The Medical Device Products segment, a new venture, generated $176,476 in sales for the nine months but incurred a net loss of $570,589 due to development activities.

Sentiment

Score: 4

Explanation: The company faces significant operational challenges, including increased net losses, reduced operating cash flow, an FDA Official Action Indicated, and ongoing supply chain disruptions for critical isotopes. While strategic initiatives like the DUF6 asset sale and new partnerships offer future potential, current performance and regulatory risks weigh heavily on the sentiment.

Positives

• Total product sales for the nine months ended September 30, 2025, increased by 2% to $10,172,036.
• Calibration & Reference Products segment sales surged by 57% to $3,301,673 for the nine months, recovering from a prior year isotope shortage.
• The Cobalt Products segment improved its net income to $571 for the nine months, up from a net loss of $18,806 in the prior year.
• The planned sale of the Fluorine Products segment and De-Conversion Facility for $12.5 million is expected to generate $10.2 million in net cash, reduce long-term liabilities by $1.62 million, and eliminate approximately $100,000 in annual operating costs.
• Regulatory approval was received for an additional Theranostics Products supplier in June 2025, with sourcing from two suppliers beginning in September 2025, aiming to stabilize sales.
• Strategic partnerships with Alpha Nuclide Inc. for distribution in China and PhanQual (with Phantech LLC) for sealed sources are expected to expand market reach and product offerings.
• A new operating lease for a second facility was secured in January 2025, with an expected startup in Q2 2026, indicating future production expansion.

Negatives

• Net loss for the three months ended September 30, 2025, was $203,601, a significant decrease from net income of $150,251 in the same period of 2024.
• The nine-month net loss increased to $477,080 in 2025 from $237,245 in 2024.
• Net cash provided by operating activities decreased substantially to $210,043 for the nine months ended September 30, 2025, from $568,215 in 2024.
• Theranostics Products sales decreased by 17% for the nine months due to temporary supplier outages and partial loss of a long-standing national account, resulting in an estimated $750,000 in lost sales.
• A global outage of Gadolinium-153 isotopes since January 2025 has resulted in significant lost sales for the Calibration & Reference Products segment, with an uncertain timeframe for supply restoration.
• The Medical Device Products segment incurred a net loss of $570,589 for the nine months due to increased development activity, despite generating initial sales.
• The company's cash and cash equivalents decreased by approximately 15% to $1,651,548 at September 30, 2025, from $1,945,523 at December 31, 2024.
• Total liabilities increased to $13,750,802 at September 30, 2025, from $12,813,960 at December 31, 2024.

Risks

• Volatility in raw material and energy costs, and inability to recover these increases from customers, could significantly increase the cost of doing business or result in lost sales.
• Reliance on a just-in-time supply chain for radioisotopes means any disruption (production outage, logistics failure, equipment malfunction, regulatory hold) could render an entire shipment unusable, leading to total loss of product and revenue, and impacting patient care or clinical trials.
• Ongoing global shortage of Gadolinium-153 isotopes since January 2025 could lead to continued lost sales in the Calibration & Reference Products segment if new suppliers are not established by 2026.
• Dependence on the U.S. Department of Energy (DOE) and its contractor for Cobalt-60 production, with risks including access to Cobalt-59 feedstock, planned maintenance at the Advanced Test Reactor (ATR) in 2027, and the ATR prioritizing Naval operations.
• If the FDA concludes that the company has failed to comply with applicable regulations following the April 2025 Official Action Indicated (OAI), it could take various actions including warning letters, penalties, product recalls, or a manufacturing and distribution hold.
• The closing of the DUF6 Asset Sale is contingent on the buyer obtaining financing and approvals from the NRC and other third parties, with no assurance it will close by the March 31, 2026, Outside Date.
• Future liquidity and capital funding requirements depend on numerous factors, and there is no assurance that additional capital and financing will be available on acceptable terms or at all.
• Dependence on a small number of customers, with sales to the top three customers accounting for approximately 30% of total gross revenue for the nine months ended September 30, 2025, and one customer accounting for 18% of Theranostics Products revenue.

Future Outlook

The company expects cash from operations, equity or debt financing, and its current cash balance to be sufficient to fund operations for the next twelve months. It anticipates stabilized sales and steady growth for Theranostics Products, primarily from its generic sodium iodide I-131 drug product and new theranostic API products. The Medical Device segment plans a Q3 2026 rollout and Q2 2027 commercial ramp-up for the EasyFill Automated Iodine Capsule System, and expects to release acquired RadVent products in early 2026. The sale of the Fluorine Products segment is expected to close by March 2026, providing significant liquidity and reducing debt. The company is working to restore Gadolinium-153 supply by 2026 and continues to seek additional critical isotope suppliers.

Management Comments

• We are currently evaluating any effects the current government shutdown might have on the NRC review process and approval for license transfer related to the DUF6 Asset Sale.
• We expect that cash from operations, equity or debt financing, and our current cash balance will be sufficient to fund operations for the next twelve months.
• We believe we are on a pathway to implement and finalize our corrective actions in response to the FDA OAI without any adverse effect on our business, results of operations and financial condition.
• We expect stabilized sales and steady sales growth for our Theranostics Products going forward, primarily from the sale of our generic sodium iodide I-131 drug product and new sales of theranostic API product.
• We expect these sales (Gadolinium-153 products) to return with a period of catch-up once we have been able to source this radioisotope.
• We expect the disposition of the Fluorine Products assets to bring in $12.45 million in gross consideration, recognizing a gain on the sale of assets of $7.5 million.
• We currently expect to use some of the proceeds (from DUF6 sale) to repay various long-term notes, totaling $1.62 million in principal and approximately $618,000 in accrued interest, leaving the Company with net cash of $10.2 million.

Industry Context

The company operates in the growing radioisotope and radiopharmaceutical market, with the theranostics market alone valued at $4.3 billion in 2024 and projected to reach $12.7 billion by 2029 (24% CAGR). Its FDA-approved generic sodium iodide I-131 drug product positions it as a domestic alternative to foreign manufacturers. The company's high energy and high activity NRC licensing, GMP compliance, and FDA licensed facility provide a competitive advantage in the theranostics space. The global supply chain for radioisotopes is complex and prone to disruptions, as evidenced by the Cobalt-57 and Gadolinium-153 shortages, impacting the broader industry.

Comparison to Industry Standards

• The theranostics market is projected to grow at a 24% compound annual growth rate from $4.3 billion in 2024 to $12.7 billion by 2029, indicating a high-growth industry where the company aims to be a key API supplier.
• The company's FDA-approved generic sodium iodide I-131 drug product is noted as the only domestic product of its type, offering a competitive advantage against a single existing foreign commercial drug manufacturer.
• The company's Calibration & Reference Products segment faces competition from a few small regional suppliers internationally and one major producer globally, with products often needing to meet Original Equipment Manufacturer (OEM) dimensional and performance standards.
• The company's reliance on the U.S. Department of Energy (DOE) and the Advanced Test Reactor (ATR) at Idaho National Lab (INL) for Cobalt-60 supply highlights a unique domestic sourcing strategy, contrasting with global reliance on research reactors that often have higher downtime frequencies for medical isotopes.

Corporate Governance

Legal Proceedings

• An FDA inspection in April 2025 at the Idaho Falls facility resulted in an Official Action Indicated (OAI). The company has developed and implemented corrective actions and submitted updates, working with the FDA to complete manufacturing changes. There is a risk of additional FDA action, including a manufacturing and distribution hold, if corrective actions are not deemed satisfactory.

Related Party Transactions

• The 2013 Promissory Note ($500,000 principal) is with the former chairman of the board and a major shareholder, with accrued interest of $354,234 at September 30, 2025. Its maturity date was extended to March 31, 2028.
• The 2018 Promissory Note ($120,000 principal) is with the current chief executive officer and chairman of the board through an affiliated entity, with accrued interest of $53,570 at September 30, 2025. Its maturity date was extended to March 31, 2028.
• The 2019 Promissory Note ($1,000,000 aggregate principal) is with the chief executive officer, chairman, former chairman, and a major shareholder, with accrued interest of $229,131 at September 30, 2025. Its maturity date was extended to March 31, 2028.
• Holders of Series C Preferred Stock, some of whom are related parties, elected to settle $90,660 of dividend payments with 1,743,457 shares of common stock during the nine months ended September 30, 2025.

Stakeholder Impact

• **Shareholders**: Increased net losses and reduced operating cash flow could negatively impact shareholder value. The pending DUF6 asset sale offers a significant cash injection and debt reduction, which could be positive. Dilution from stock-based compensation and dividend payments in stock continues.
• **Employees**: Increased headcount and pay rates contributed to higher salary and contract labor expenses, suggesting stable or growing employment. The new facility build-out indicates future operational expansion and potential job creation.
• **Customers**: Supply interruptions for Theranostics Products and the global shortage of Gadolinium-153 for Calibration & Reference Products have led to lost sales, potentially impacting customer satisfaction and reliability of supply. The FDA OAI could also affect product availability if further actions are taken.
• **Creditors**: The extension of maturity dates for significant promissory notes, including those with related parties, defers repayment risk but also prolongs the period of outstanding debt. The DUF6 asset sale proceeds are earmarked for debt repayment, which would benefit creditors.
• **Suppliers**: The company's dependence on a few key suppliers for critical radioisotopes creates risk for both the company and its suppliers if disruptions occur. Efforts to diversify suppliers (e.g., for Theranostics Products) could benefit new suppliers.

Next Steps

• Complete corrective actions in response to the FDA Official Action Indicated (OAI) and undergo FDA reinspection.
• Continue efforts to establish new suppliers for Gadolinium-153 isotopes to restore supply by 2026.
• Monitor and facilitate the NRC review process for the transfer of the Fluorine Products segment license to the buyer, aiming for the DUF6 Asset Sale to close by March 31, 2026.
• Proceed with the build-out of the new second facility for future production, with an expected startup in Q2 2026.
• Continue development and prepare for the Q3 2026 rollout and Q2 2027 commercial ramp-up of the EasyFill Automated Iodine Capsule System.
• Prepare for the early 2026 release of the RadVent Swirler and Tru-Fit Mouthpiece products.
• Explore opportunities to further develop cobalt-60 and other high-energy and high-activity products and sales.

Key Dates

Recommendation

The company faces significant challenges, including an increased net loss, reduced operating cash flow, and an FDA Official Action Indicated, which introduces regulatory uncertainty and potential operational disruptions. Supply chain issues for critical isotopes continue to impact sales in key segments. However, the pending $12.5 million DUF6 asset sale is a major positive, expected to significantly improve liquidity, reduce debt, and remove liens on other assets. Strategic initiatives in Medical Devices and international partnerships also offer long-term growth potential. Given the high risks but also the substantial potential upside from the asset sale and strategic developments, a 'hold' recommendation is appropriate for investors willing to monitor the execution of these initiatives and the resolution of regulatory and supply chain issues.

Keywords

radioisotopes, theranostics, cobalt-60, calibration standards, medical devices, SEC filing, 10-Q, financial results, supply chain, FDA OAI, uranium de-conversion, asset sale, liquidity, corporate governance